N-Arylsulfonylated\nC‑Homoaporphines as a New\nClass of Antiplatelet and Antimicrobial Agents

A series of novel N-arylsulfonylated C-homoaporphine\nalkaloids\nwere synthesized under microwave irradiation and evaluated for their <i>in vitro</i> antiplatelet and antimicrobial activities. Among\nthe series, compounds <b>12a</b>, <b>12c</b>, <b>12e</b>, <b>12f</b>, <b>12h</b>, <b>12j</b>, <b>12k</b>, <b>12m</b>, and <b>12o</b> demonstrated highly potent\n(∼3-fold) platelet aggregation inhibitory activity than acetylsalicylic\nacid (IC<sub>50</sub> = 21.34 μg/mL). Several N-arylsulfonylated\nC-homoaporphines also exhibited promising antimicrobial activity against\nvarious strains, including <i>Macrophoma phaseolina</i>, <i>Trichoderma reesei</i>, and <i>Aspergillus niger</i>, with minimum inhibitory concentrations (MIC) of 12.5, 6.25, and\n12.5 μg/mL, respectively, comparable to Ketoconazole [MIC =\n12.5 μg/mL (MP and AN strain); 6.25 μg/mL (TR strain)]. <b>12h</b> showed potent antibacterial activity (IC<sub>50</sub> =\n6.25 μg/mL against <i>Escherichia coli</i> and <i>Bacillus subtilis</i>) compared to Ampicillin (IC<sub>50</sub> = 12.5 μg/mL). After thorough structure–activity relationship\n(SAR) and <i>in silico</i> studies, C-homoaporphines were\nidentified as a novel class of antiplatelet and antimicrobial agents.